JMGC buys stakes in profitable, founder-led companies that are worth more than they look. We fix positioning, generate demand, and build the experience that drives retention.

We don't borrow against the businesses we buy.
We're not working toward an exit, because there isn't one.
The founder who built it keeps running it.
JMGC owns two operating companies outright. Both were built in-house, and both work on every investment the firm makes.

A leading global strategy and CX firm headquartered in New York City serving the world's leading brands. Enterprise brand, experience, and demand systems for Thermo Fisher Scientific, Starbucks, Carnival Corporation, Levi's, and Saks Fifth Avenue.
g-co.agency→
Simulates how customers, clinicians, and executives evaluate a decision before it is made.
acumen-data.com→JMGC is a private holding company that invests its own capital in profitable, founder-led businesses across specialty services, healthcare and life sciences, software, and premium consumer categories.
We were established on a straightforward observation. In fragmented markets, the businesses with the strongest underlying quality are frequently not the ones earning the highest returns. Competitive position is determined less by capability than by how that capability is understood — by customers, by buyers, and by the market itself. That distinction is measurable, and it is addressable.
We acquire businesses where it is the principal constraint, and we work systematically to remove it.
2026
New York, New York
Permanent capital. No fund life, no exit obligation.
We pursue a focused strategy in the lower middle market, where the disparity between operational quality and commercial performance is widest and where institutional capital is least present.
Our thesis is that under-defined market position imposes a quantifiable cost on the businesses we evaluate. It constrains pricing power, raises customer acquisition cost, and weakens retention. Each is observable in the financial statements before an acquisition, and each is responsive to disciplined intervention afterward.
We concentrate our capital and our attention. We expect to hold a limited number of investments and to be materially involved in each.
Specialty business services. Healthcare and life sciences services. Vertical software and data. Premium recurring consumer services. Consumables distributed through professional channels.
We do not pursue businesses in which distribution access, capital intensity, labor arbitrage, or regulatory constraint is the primary determinant of performance. In those settings our approach does not create advantage, and we decline them.
Our value creation approach is applied consistently across the portfolio. It is not advisory, and it is not delivered through third parties. It is executed by our own team, in a defined sequence, over a defined period.
We define the category in which the business competes, establish its differentiation, and reset pricing to reflect the quality of what is delivered.
We rebuild the systems through which the business is discovered and evaluated, with particular attention to how buyers now search, compare, and decide.
We reconstruct the customer journey — how the business is encountered, understood, and retained — as a commercial system rather than a design exercise.
We install the technology and operating discipline required to sustain the position, so it holds without depending on any one person.
We identify a limited number of variables that determine the outcome and address them completely, rather than pursuing broad transformation. In our experience, sequence and completeness matter more than scope.
Our diligence process incorporates proprietary decision intelligence technology developed within the firm. Prior to committing capital, we model the target’s customer base directly — how the business is perceived relative to its competitors, the pricing the market will support, and the conditions under which customers would leave.
This allows us to evaluate our central investment hypothesis before close rather than after, and to underwrite our value creation plan against evidence rather than assumption.
The following principles have governed our work for more than a decade and now govern the deployment of our capital.
How a business is perceived, encountered, and understood is not presentational. It is among the most defensible advantages available in a fragmented market, and it compounds.
Companies systematically over-invest in prospective customers and under-invest in existing ones. The correction is among the most reliable sources of value we encounter.
Any commercial result can be separated into its constituent variables. Understanding which of them determine the outcome is the foundation of our underwriting and of our operating work.
Every commitment forecloses another. We hold a limited number of positions in order to be materially useful in each.
We cannot forecast outcomes with certainty. We can test hypotheses before committing capital, and we do.
Compounding requires time. We have structured the firm so that we are never required to sell.
We recognize that a decision to sell a portion of a business is rarely a purely financial one.
Our approach is built on continuity. We do not replace management as a matter of course, we do not employ significant leverage, and we are not working toward a predetermined exit. Founders who partner with us generally remain involved, retain meaningful ownership, and participate in the value created.
We are not seeking to change what a business fundamentally is. We are seeking to ensure that the market understands it accurately, prices it accordingly, and does not readily leave it.
Mr. Gonzalez is also the founder of G & Co., a global strategy and experience consultancy serving Thermo Fisher Scientific, Starbucks, Carnival Corporation, Levi’s, and Saks Fifth Avenue. Under his leadership the firm has grown to serve enterprise clients across life sciences, consumer, and travel, generating substantially all of its revenue through inbound demand.
He is additionally the founder of Acumen Labs, a decision intelligence platform used to model stakeholder behavior in complex commercial decisions, which supports the firm’s underwriting process.
His work has been recognized by the Council of Fashion Designers of America, the Association of National Advertisers, the Wall Street Journal, and Inc.
We evaluate opportunities on a continuous basis and welcome direct approaches from founders, owners, and intermediaries.
66 Hudson Blvd E, New York, NY 10018
